Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
16.27
-0.35 (-2.11%)
At close: Feb 21, 2025, 4:00 PM
16.50
+0.23 (1.41%)
After-hours: Feb 21, 2025, 7:01 PM EST
Viridian Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Viridian Therapeutics stock have an average target of 36.44, with a low estimate of 20 and a high estimate of 61. The average target predicts an increase of 123.97% from the current stock price of 16.27.
Analyst Consensus: Buy
* Price targets were last updated on Jan 7, 2025.
Analyst Ratings
The average analyst rating for Viridian Therapeutics stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Buy | 5 | 5 | 4 | 4 | 4 | 4 |
| Hold | 2 | 2 | 2 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $38 | Strong Buy | Reiterates | $38 | +133.56% | Jan 7, 2025 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $27 | Buy → Hold | Downgrades | $27 | +65.95% | Dec 19, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $44 → $47 | Buy | Maintains | $44 → $47 | +188.88% | Dec 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $34 | Strong Buy | Reiterates | $34 | +108.97% | Dec 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $34 | Strong Buy | Reiterates | $34 | +108.97% | Dec 16, 2024 |
Financial Forecast
Revenue This Year
324.36K
from 314.00K
Increased by 3.30%
Revenue Next Year
235.30K
from 324.36K
Decreased by -27.46%
EPS This Year
-4.07
from -5.31
EPS Next Year
-4.31
from -4.07
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1.1M | 1.1M | 96.9M | |||
| Avg | 324,360 | 235,304 | 39.9M | |||
| Low | 196,000 | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 234.4% | 223.7% | 41,087.2% | |||
| Avg | 3.3% | -27.5% | 16,835.6% | |||
| Low | -37.6% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -3.47 | -3.33 | -2.44 | |||
| Avg | -4.07 | -4.31 | -4.14 | |||
| Low | -4.11 | -5.79 | -6.39 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.